Skip to main
ONC
ONC logo

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines, a biotechnology company focused on oncology, reported a significant increase in core drug Brukinsa's sales, rising 105% year-over-year to US$2.6 billion, which constitutes 68% of its total revenue for 2024, indicating robust market demand and revenue generation. Furthermore, Tevimbra's sales also experienced a positive shift, increasing 16% year-over-year to US$621 million, outperforming a key competitor, highlighting BeOne's competitive edge in the oncology market. The company ended 2024 with US$2.6 billion in cash, providing a strong liquidity position that supports future growth and expansion initiatives within the industry.

Bears say

BeiGene's financial outlook remains negative primarily due to a substantial decrease in cash flow from operations, which fell from US$188 million in the third quarter to US$75 million in the fourth quarter of 2024, driven by increased receivables and inventory levels. The company also reported a net loss of US$645 million, albeit a 27% reduction year-over-year, indicating persistent financial challenges despite some improvement. Additionally, revised market share estimates and peak sales projections for key products, particularly in light of the struggles within the TIGIT class of drugs, further contribute to concerns about BeiGene's revenue prospects moving forward.

BeiGene Ltd (ONC) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 3 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $320.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $320.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.